1. China Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Cathay Biotech, Inc. Class A

Cathay Biotech, Inc. Class A

SSSE:688065
36.62
CNY
-0.09
(-0.25%)
0.88EPS
52.60P/E
34.51BMarket Cap
Oct 31Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.77
2.34
3.01
3.77
2.76
4.05
4.19
3.63
5.08
4.82
4.93
Basic EPS, GAAP
0.28
0.57
0.8
0.94
0.84
1.02
0.95
0.63
0.84
0.82
0.91
Free Cash Flow per Basic Share
-0.86
-1.61
-0.72
-0.3
-0.46
-1.51
-5.83
-1.72
-0.04
-0.5
- -
Dividend per Share
- -
- -
0.31
0.24
0.01
0.58
0.36
0.24
0.24
0.46
0.03
Book Value per Share
2.32
4.18
6.01
8.84
17.8
18.26
18.77
19.14
19.72
24.54
24.62
Tangible Book Value per Share
2.26
3.79
5.6
8.4
17.41
16.94
17.44
17.93
18.55
23.53
23.26
Basic Weighted Avg Shares
525
583
583
508
543
583
582
582
582
684
719
Sales/Revenue/Turnover
929
1,363
1,757
1,916
1,497
2,363
2,441
2,114
2,958
3,295
3,545
Operating Margin (%)
20.86
31.62
29.19
29.55
33.07
22.65
18.56
12.93
16.46
20.46
21.58
Depreciation Expense
35
46
73
116
118
169
265
286
321
316
- -
Net Income, GAAP
145
333
466
479
458
595
553
367
489
561
654
Effective Tax Rate (%)
26.35
15.29
13.81
13.85
12.18
12.55
11.97
9
13.4
15.97
13.78
Profit Margin (%)
15.66
24.42
26.54
24.99
30.57
25.16
22.66
17.34
16.53
17.02
18.46
Working Capital
367
101
310
1,666
8,010
10,177
7,051
4,161
4,469
9,725
9,684
LT Debt
- -
- -
- -
80
- -
- -
961
245
613
189
378
Total Equity
1,219
2,197
3,157
4,642
11,484
14,674
15,038
14,773
15,101
21,315
21,588
Return on Invested Capital (%)
- -
19.56
16.75
12.32
5.58
4.69
3.94
2.52
2.84
2.74
2.72
Return on Capital (%)
- -
19.07
16.88
12
5.62
4.24
3.24
2.16
3.14
3.09
3
Return on Common Equity (%)
- -
19.48
17.42
12.28
6.09
5.65
5.12
3.31
4.31
3.84
3.71

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
314
790
330
LT Borrowings
189
303
378
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
721
721
721
Market Capitalization
35,920
35,668
34,514

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
11,731
12,267
11,963
Cash, Cash Equivalents & STI
9,252
9,406
9,298
Accounts Receivable, Net
297
346
421
Inventories
1,440
1,401
1,407
Total Current Liabilities
2,006
2,402
2,279
Payables & Accruals
- -
- -
- -
ST Debt
314
790
330
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.37%
41.15%
Free Cash Flow
- -
357.61%
1,415.99%
Net Income, GAAP
- -
7.46%
14.68%
Sales/Revenue/Turnover
- -
19.81%
11.4%
Total Cash Common Dividend
- -
1,744.9%
122.34%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
685
760
771
743
2,958
2025
776
895
- -
750
3,295
2026
875
1,026
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.24
0.17
0.25
0.84
2025
0.23
0.24
- -
0.15
0.82
2026
0.23
0.29
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.01
0.2
0.02
0.24
2025
0.02
- -
- -
0.01
0.46
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xiucai Liu
Full Time Employees
1,761
Sector
Process industries
Industry
Chemicals: specialty
Address
Building #5 Shanghai SH China 201114
IPO Date
Aug 7, 2020
Website
cathaybiotech.com
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
Cathay Biotech Inc. (688065.SS) researches, develops, produces and sells bio-based materials utilizing synthetic biology and bio-manufacturing technology in China and internationally. The company, founded in 2000 and headquartered in Shanghai at Building 5, 1690 Cailun Road, Zhangjiang Hi-Tech Park, focuses on the polyamide industry value chain; its core products include biological long-chain diacids such as sebacic acid (DC10), octadecanedioic acid (DC18) and other dibasic acids (DC11-DC36); bio-based pentamethylene diamine (PDA or DN5); and a series of bio-based polyamides including TERRYL for textile applications and ECOPENT for engineering materials; these serve industries including textiles, pharmaceuticals, perfumes, automobiles, electronic appliances, consumer goods, engineering materials and transportation. Cathay Biotech operates production sites in Jinxiang and Wusu, with R&D centers in Shanghai; it exports products globally under its brands. In recent developments, the company signed a joint venture agreement with South Korea's 3P.COM Co. Ltd. in late 2024 to develop sustainable bio-based composite materials; it partnered with Hefei Municipal Government and China Merchants Innovation Technology in May 2024, followed by a December 2024 announcement for joint investment in Yaoyang Biotechnology (Shanghai) via subsidiaries; earlier in 2023, it entered a major strategic collaboration with China Merchants Group encompassing capital raising, bio-based polyamide procurement targets through 2025, and financing support; it continues expanding with bio-based composite innovations showcased at events like JEC World 2025, SNEC 2024 and CHINAPLAS 2024, including applications in aviation temperature-controlled containers.